title: Expression of the significance of silent information regulator type-1 in Angioimmunoblastic T-cell lymphoma is greater association with tumorigenesis and has strong implications for adverse prognosis.
abstract: Silent information regulator type-1 (SIRT1) is the best-studied member of the Sirtuin (Sir2) family of nicotinamide dinucleotide (NAD)-dependent class III histone deacetylases (HDACs). Rrecently, it is suggested that SIRT1 may be involved in the development of malignant tumors including mouse lymphoma, but has not yet been explored in Angioimmunoblastic T-cell lymphoma (AITL). Therefore, we investigated the prevalence and the prognostic impact of SIRT1 expression in AITL. Immunohistochemical expression of SIRT1, p53 were evaluated by using a 2 mm core from 45 AITL patients. Positive expression of SIRT1 was seen in 71.11% (32 of 45) of patients and p53 expression were seen in 53.33% (24 of 45). SIRT1 and p53 expression were significantly associated with shorter PFS by univariate analysis (P=0.009 and P < 0.001, respectively), multivariate analysis also shows that SIRT1 expression relate to worse prognosis. We also suggest inferior survival in AITL with the combined expression of SIRT1 and clinical characteristics of high IPI scores, high clinical stage, increased serum LDH, decreased HGB and increased γ-Globulin. In conclusion, our results indicate that SIRT1 is strongly expressed in AITL and it act as a clinically significant prognostic indicator for AITL patients, may also serve as a therapeutic target in AITL.
authors.affiliation: a Second Affiliated Hospital of Harbin Medical University , Harbin , Heilongjiang Province , P. R. of China.
authors.forename: Yuyue
authors.initials: Y
authors.lastname: Ren
authors.affiliation: b The First Affiliated Hospital of Harbin Medical University , Harbin , Heilongjiang Province , P. R. of China.
authors.forename: Yunhe
authors.initials: Y
authors.lastname: Gu
authors.affiliation: a Second Affiliated Hospital of Harbin Medical University , Harbin , Heilongjiang Province , P. R. of China.
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.affiliation: a Second Affiliated Hospital of Harbin Medical University , Harbin , Heilongjiang Province , P. R. of China.
authors.forename: Jinghua
authors.initials: J
authors.lastname: Wang
authors.affiliation: a Second Affiliated Hospital of Harbin Medical University , Harbin , Heilongjiang Province , P. R. of China.
authors.forename: Xiaoyun
authors.initials: X
authors.lastname: Li
authors.affiliation: a Second Affiliated Hospital of Harbin Medical University , Harbin , Heilongjiang Province , P. R. of China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Wang
authors.affiliation: a Second Affiliated Hospital of Harbin Medical University , Harbin , Heilongjiang Province , P. R. of China.
authors.forename: Haiyan
authors.initials: H
authors.lastname: Gao
authors.affiliation: a Second Affiliated Hospital of Harbin Medical University , Harbin , Heilongjiang Province , P. R. of China.
authors.forename: Xiushuai
authors.initials: X
authors.lastname: Dong
authors.affiliation: a Second Affiliated Hospital of Harbin Medical University , Harbin , Heilongjiang Province , P. R. of China.
authors.forename: Yaoyao
authors.initials: Y
authors.lastname: Tian
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D063646:Carcinogenesis / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D007770:L-Lactate Dehydrogenase / Q000097:blood / Q000235:genetics; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D056564:Sirtuin 1 / Q000235:genetics* / Q000378:metabolism; D016019:Survival Analysis; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism; D014750:Vincristine / Q000627:therapeutic use; D005719:gamma-Globulins / Q000235:genetics / Q000378:metabolism
chemical_list: D016159:Tumor Suppressor Protein p53; D005719:gamma-Globulins; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D007770:L-Lactate Dehydrogenase; C447939:SIRT1 protein, human; D056564:Sirtuin 1; D011241:Prednisone
keywords: AITL; SIRT1; prognosis; tumor; tumorigenesis